RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine

Background Limited information is available on the effectiveness of the BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine, especially in the elderly, despite the fact that it is approved in more than 50 countries. Methods RBD-specific antibody titres, as a rapidly available and highly predictive surrogat...

Full description

Saved in:

Bibliographic Details
Published in:	BMC infectious diseases Vol. 22; no. 1; pp. 87 - 11
Main Authors:	Ferenci, Tamás, Sarkadi, Balázs
Format:	Journal Article
Language:	English
Published:	London BioMed Central 24.01.2022 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Accreditation Age Aged Antibodies Antibody Formation Antibody response BBIBP-CorV Beijing Coronaviruses COVID-19 COVID-19 vaccines Disease Humans Infections Infectious Diseases Internal Medicine Laboratories Medical Microbiology Medicine Medicine & Public Health Older people Parasitology SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Sex Statistical analysis Testing Tropical Medicine Vaccination Vaccine Vaccines Viral antibodies Viral diseases Beijing Hungary Beijing China China COVID-19 SARS-CoV-2 Vaccine BBIBP-CorV Antibody response
ISSN:	1471-2334, 1471-2334
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!